Super-Hypofractionated Partial Breast Irradiation After Breast-Conserving Surgery for Early-Stage Low-Risk Breast Cancer: a Prospective, Single-arm Trial
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Incidence of acute adverse reactions
研究概览
简要总结
Partial breast irradiation is currently a hot topic in clinical research, but the appropriate population and appropriate irradiation The technology and dose fractionation mode are still inconclusive. Foreign studies have mostly selected patients with low risk of recurrence. Breast-conserving surgeries for early-stage breast cancer are increasing year by year in China. It is necessary to conduct prospective clinical studies to explore the Chinese population suitable for partial breast irradiation and the appropriate radiotherapy dose fractionation model. A preliminary study in our center has compared the safety and efficacy of a 2-week schedule of partial breast irradiation (40Gy/10f) and a 3-week schedule of whole-breast radiotherapy (43.5Gy/15f) in patients with early-stage low-risk breast cancer after breast-conserving surgery. , preliminary results show that the 2-week partial breast irradiation regimen is safe and effective. This study plans to continue to select low-risk breast-conserving patients, use extracorporeal intensity-modulated radiotherapy technology, refer to the radiotherapy dose fractionation model of the FAST-Forward study, and give partial breast irradiation 5.2 Gy/f/d, a total of 5 times, with a total dose of 26Gy, to further shorten the time The radiotherapy time is 1 week, and the acute and late adverse reactions of radiotherapy and the local control of the tumor are prospectively observed. Provide evidence for conducting a national multi-center phase III clinical randomized study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 45 Years 至 74 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •≥45 years old, <75 years old women
- •Life expectancy >5 years
- •Start radiotherapy within 12 weeks after breast-conserving surgery (or within 8 weeks from the end of chemotherapy)
- •Invasive ductal carcinoma grade 1-2, or mucinous carcinoma, papillary carcinoma, canalicular carcinoma, medullary carcinoma; primary tumor
- •≤3.0cm; both pN0 (axillary dissection or sentinel lymph node biopsy)
- •Low-risk DCIS: tumor ≤2.5cm, low to medium grade; axillary surgery is not required or pN0
- •Single focus (with MRI diagnosis)
- •Vascular tumor thrombus negative
- •ER and/or PR positivity (defined as strong positivity in >1% of tumor cell nuclei)
- •Negative pathological margin≥2mm
- •Place metal markers on the tumor bed
- •Sign the informed consent form
排除标准
- •Multiple primary tumors
- •Invasive ductal carcinoma grade 3
- •Invasive micropapillary carcinoma
- •Lobular carcinoma in situ
- •Invasive lobular carcinoma
- •Simple nipple paget's disease
- •Oncoplastic surgery
- •Neoadjuvant chemotherapy or neoadjuvant endocrine therapy
- •Previous or simultaneous contralateral breast cancer
- •History of ipsilateral chest wall radiotherapy
- •Have active collagen vascular disease
结局指标
主要结局
Incidence of acute adverse reactions
时间窗: up to 6 months
次要结局
- Incidence of late adverse reactions(through study completion, an average of 5 year)
- Survival(through study completion, an average of 5 year)
研究者
Shulian Wang
Professor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences